Orchidia Pharmaceutical Industries
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Orchidia Pharmaceutical Industries - overview
Established
1993
Location
El Obour City, Cairo, Egypt
Primary Industry
Pharmaceuticals
About
Orchidia Pharmaceutical Industries specializes in the development, manufacturing, and distribution of pharmaceutical products, focusing on high-quality, accessible healthcare solutions. Founded in 1993 and headquartered in El Obour City, Egypt, Orchidia Pharmaceutical Industries focuses on pharmaceuticals, specifically producing and distributing a variety of healthcare products. The company has undergone strategic changes since its inception, including a significant focus on expanding its market reach. The leadership team includes CEO Ossama Abbas and Rehab Gendy.
In March 2026, a consortium led by SPE Capital, along with EBRD, Proparco, and BIO Invest, invested in Orchidia Pharmaceutical Industries. Financial terms were not disclosed. Orchidia provides a robust suite of offerings primarily focused on the pharmaceutical sector. Their core product line includes prescription medications, over-the-counter drugs, and specialized formulations.
By leveraging advanced technology and research, Orchidia aims to enhance product accessibility and efficacy for healthcare providers and patients alike. The company serves a diverse clientele across various geographical markets, particularly in the Middle East and North Africa, where there is a growing demand for quality healthcare solutions. Orchidia's revenue model is primarily structured around B2B partnerships, including collaborations with hospitals, pharmacies, and healthcare providers, through contractual agreements that allow access to their suite of pharmaceuticals. The revenue is generated from direct sales of products, with pricing strategies tailored to meet the needs of various clients, ensuring a sustainable income stream while delivering value to partners and healthcare professionalsThe company aims to penetrate new markets, specifically targeting regions in North Africa and the Middle East.
The recent funding will support these initiatives and help enhance their research and development capabilities, thus enabling Orchidia to meet the rising demand for innovative healthcare solutions.
Current Investors
Proparco, EBRD, SPE Capital
Primary Industry
Pharmaceuticals
Sub Industries
Optometrists & Opticians Products and Services, Pharmaceutical Research & Development, Biomaterials
Website
www.orchidiapharma.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Orchidia Pharmaceutical Industries - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Orchidia Pharmaceutical Industries | - | ||||||||
| LP Direct, Trade Sale | Completed | Orchidia Pharmaceutical Industries | - | ||||||||
| Growth | Completed | Orchidia Pharmaceutical Industries | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.